HSP90 inhibitor potentiates the activity of mTOR inhibitor against human breast cancer

The research group led by Prof. DING Jian in Shanghai Institute of Materia Medica, CAS established the platform in an aim of discovery and research of mTOR kinase inhibitors.They found mTOR inhibition led to activation of upstream RTKs and AKT, which may attenuate the efficacy of mTOR kinase inhibitors. Combination therapy is a promising strategy to improve the efficacy of mTOR inhibitors.